Madrigal Q1 cash burn $84.1M; resmetirom NDA on track for Q2 2023 with Breakthrough Therapy

MADRIGAL PHARMACEUTICALS, INC.

2023-Q1 EPS reported -$4.23

Cash and securities $329.5M at March 31, 2023, down from $358.8M at Dec 31, 2022.
Operating expenses $78.3M for Q1 2023, up from $57.6M in Q1 2022; R&D $62.2M, G&A $16.2M.
Resmetirom NDA for NASH with fibrosis remains on track for Q2 2023; FDA Breakthrough Therapy designation received.
MAESTRO-NASH trial enrollment complete; primary results to be presented at EASL in June 2023.
Interest income rose to $3.8M from $0.1M; interest expense $2.3M from loan facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MADRIGAL PHARMACEUTICALS, INC. reported financial results for first quarter 2023.

Period: first quarter 2023
Result: reported results

Exact text from the filing

On May 9, 2023, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-138931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.